Funding for this research was provided by:
Bill and Melinda Gates Foundation (OPP1053616)
Siemens Foundation (OPP-00006234)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Received: 2 June 2020
Accepted: 25 August 2020
First Online: 3 September 2020
Ethics approval and consent to participate
: This Phase I trial was conducted in accordance with Good Clinical Practice guidelines and institutional procedures and guidelines. Each village provided community permission and all participants provided informed consent. The study was approved by the Mali ethics review board (Faculté de Médecine de Pharmacie et d’OdontoStomatologie, Bamako), U.S. National Institute of Allergy and Infectious Diseases (NIAID, National Institutes of Health [NIH], Bethesda, MD) institutional review board, and Mali national regulatory authority, and was conducted under FDA IND 16251.
: Not applicable.
: The authors declare that they have no competing interests.